Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.

Rui-Lian ChenJun ZhaoXu-Chao ZhangNa-Na LouHua-Jun ChenXue YangJian SuZhi XieQing ZhouHai-Yan TuWen-Zhao ZhongHong-Hong YanWei-Bang GuoYi-Long WuJin-Ji Yang

Published in: BMC cancer (2018)

C-Met overexpression co-exists with ALK rearrangement in a small population of advanced NSCLC. There may be a trend of favorable efficacy of crizotinib in such co-altered patients.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
end stage renal disease
cell proliferation
ejection fraction
newly diagnosed
chronic kidney disease
transcription factor
prognostic factors
patient reported outcomes